988 Results

People

  1. Lesokhin
    Lesokhin
  2. Landgren
    Landgren
  3. Hassoun
    Hassoun
  4. Mailankody
    Mailankody
  5. Landau
    Landau
  6. Giralt
    Giralt
  7. Korde
    Korde
  8. Hultcrantz
    Hultcrantz
  9. Chung
    Chung
  10. Shah
    Shah

Groups

  1. Center for Hematologic Malignancies (988)
  2. Department of Medicine (988)
  3. Hematologic Malignancies, Division of (988)
  4. Myeloma (988)
  5. Hematologic Malignancies Research (651)
  6. Survivorship Research (356)
  7. Sloan Kettering Institute Postdocs (292)
  8. Bone Marrow Transplant (289)
  9. Epidemiology and Biostatistics (209)
  10. Biostatistics Service (175)
  1. "Myeloma"
Formats
  1. Meeting Abstract (543)
  2. Journal Article (358)
  3. Review (36)
  4. Research Letter (19)
  5. Book Section (10)
  6. Guidelines (10)
  7. Correspondence (6)
  8. Editorial (5)
  9. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (988)
  2. Department of Medicine (988)
  3. Hematologic Malignancies, Division of (988)
  4. Myeloma (988)
  5. Hematologic Malignancies Research (651)
  6. Survivorship Research (356)

More Groups

People
  1. Alexander Lesokhin (363)
  2. Carl Landgren (336)
  3. Hani Hassoun (329)
  4. Sham Mailankody (282)
  5. Malin Hultcrantz (260)
  6. Heather Landau (239)

More People

Years
  1. 2025 (13)
  2. 2024 (69)
  3. 2023 (115)
  4. 2022 (96)
  5. 2021 (76)
  6. 2020 (95)

More Years

Publications
  1. Blood (303)
  2. Clinical Lymphoma, Myeloma and Leukemia (96)
  3. Journal of Clinical Oncology (85)
  4. Haematologica (41)
  5. Biology of Blood and Marrow Transplantation (29)
  6. Blood Cancer Journal (22)

More Publications

Publishers
  1. American Society of Hematology (324)
  2. Elsevier Inc. (159)
  3. American Society of Clinical Oncology (87)
  4. Nature Publishing Group (83)
  5. Ferrata Storti Foundation (41)
  6. American Association for Cancer Research (34)

More Publishers

Results (988)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Waldenström macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2024, NCCN Clinical Practice Guidelines in Oncology
    Guidelines

    Kumar, S. K.; Callander, N. S.; Adekola, K.; Anderson, L. D. Jr; Baljevic, M.; Baz, R.; Campagnaro, E.; Castillo, J. J.; Costello, C.; D'Angelo, C.; more...
    Journal of the National Comprehensive Cancer Network (2024)

    Fulltext@MSK | Save
  • Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups
    Journal Article

    Shah, U. A.; Moshier, E.; Derkach, A.; Huang, Y.; Mailankody, S.; Tan, C. R.; Maclachlan, K.; Hultcrantz, M.; Korde, N.; Hassoun, H.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Nivolumab and daratumumab combination regimens for the treatment of relapsed and refractory multiple myeloma: Results of a randomized phase I/II clinical trial
    Journal Article

    Abdallah, A. O.; Lesokhin, A.; Wrobel, T.; Jamroziak, K.; Dytfeld, D.; Touzeau, C.; Suvannasankha, A.; Leleu, X.; Silbermann, R.; Khan, A. M.; more...
    Frontiers in Hematology (2023)

    Fulltext@MSK | Save
  • Treatment outcomes and prognostic factors with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus RVd plus autologous stem cell transplantation (ASCT) in African American (AA) patients (pts) with newly diagnosed multiple myeloma (NDMM) in the DETERMINATION phase 3 trial
    Meeting Abstract

    Houde, C. A.; Khan, A.; Jacobus, S. J.; Hassoun, H.; Anderson, L. D. Jr; Merz, L. E.; Zon, R. L.; Efebera, Y.; Buck, T.; Innis-Shelton, R. D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Dose escalation of ISB 1342, a novel CD38xCD3 bispecific antibody, in patients with relapsed / refractory multiple myeloma (RRMM)
    Meeting Abstract

    Kapoor, P.; Stevens, D. A.; Leleu, X.; Merzoug, K. B.; Karlin, L.; Manier, S.; Chalopin, T.; Hulin, C.; Perrot, A.; Berdeja, J. G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Updated safety and efficacy results of ABBV-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Vij, R.; Kumar, S. K.; D'Souza, A.; McKay, J. T.; Voorhees, P. M.; Chung, A.; Tuchman, S. A.; Korde, N.; Weisel, K.; Teipel, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of elranatamab monotherapy in the phase 2 magnetismm-3 trial in relapsed or refractory multiple myeloma (RRMM)
    Meeting Abstract

    Tomasson, M.; Iida, S.; Niesvizky, R.; Mohty, M.; Bahlis, N. J.; Martinez-Lopez, J.; Koehne, G.; Otero, P. R.; Prince, H. M.; Viqueira, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Selinexor, ixazomib, pomalidomide and dexamethasone in functionally high-risk multiple myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) sub-protocol Y3
    Meeting Abstract

    Richter, J.; Zonder, J. A.; Nathwani, N.; Bianchi, G.; Hofmeister, C. C.; Vij, R.; Pianko, M.; Kaur, G.; Hultcrantz, M.; Wozniak, K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical factors associated with cytokine release syndrome and dosing recommendations for restarting elranatamab following an interruption
    Meeting Abstract

    Niesvizky, R.; Arnulf, B.; Mohty, M.; Nooka, A. K.; Manier, S.; Tomasson, M.; Bahlis, N. J.; Irby, D.; Hibma, J.; Viqueira, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Risk factors of smoldering multiple myeloma: Results from the screened iStopMM study
    Meeting Abstract

    Thorsteinsdottir, S.; Sverrisdottir, I.; Rögnvaldsson, S.; Ekberg, S.; Hultcrantz, M.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B.; Sigurdardottir, M.; Thorsteinsdottir, I.; more...
    Blood (2023)

    Fulltext@MSK | Save